Vaccine boosters enhance the cross-reactivity of neutralizing antibody responses against SARS-CoV-2 omicron variant

A group from Department of Pathology, Massachusetts General Hospital, Boston, MA, USA, etc. has reported that vaccine boosters enhance the cross-reactivity of neutralizing antibody responses against SARS-CoV-2 omicron variant.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687472/

Neutralization titers of sera from 239 individuals who had been fully-vaccinated with one of three vaccines approved in the United States—mRNA-1273, BNT162b2, or Ad26.COV2.S were evaluated against wild type, Delta and Omicron variants (BNT162b2 manufactured by Pfizer-BioNTech, mRNA1273 manufactured by Moderna or as an adenovirus vectored vaccine (Ad26.COV2.S) manufactured by Janssen/Johnson & Johnson).

Cross-neutralization of Omicron variant was substantially higher in individuals who received three doses of either mRNA vaccine (GMNT increase of 19-fold for mRNA-1273 and 27-fold for BNT162b. Interestingly, Ad26.COV2.S vaccinees boosted with mRNA-1273 showed substantially higher wild type, Delta, and Omicron pseudovirus neutralization relative to those who received Ad26.COV2.S alone.

These data suggest that booster vaccines are quite effective in preventing Omicron variant infection.